Recursion Pharmaceuticals Inc reports results for the quarter ended in September 30 - Earnings Summary

• Recursion Pharmaceuticals Inc RXRX.OQ reported a quarterly adjusted loss of 34 cents​​ per share for the quarter ended September 30, higher than the same quarter last year, when the company reported EPS of -43 cents. The mean expectation of eight analysts for the quarter was for a loss of 35 cents per share. Wall Street expected results to range from -40 cents to -28 cents per share.

• Revenue rose 147.6% to $26.08 million from a year ago; analysts expected $29.84 million.

• Recursion Pharmaceuticals Inc's reported EPS for the quarter was a loss of 34 cents​.

• The company reported a quarterly loss of $95.84 million.

• Recursion Pharmaceuticals Inc shares had risen by 5.8% this quarter and lost 29.3% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 4.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy," 6 "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "hold"

Wall Street's median 12-month price target for Recursion Pharmaceuticals Inc is 10.00

This summary was machine generated from LSEG data November 7 at 05:14 a.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)